8.3.2. improving quality life men diagnosed pca. 8.3.2.1. men undergoing local treatments men localised disease, nurse-led multi-disciplinary rehabilitation (addressing sexual functioning, cancer worry, relationship issues, depression, managing bowel urinary function problems) provided positive short-term effects (four months) sexual function (effect size 0.45) long-term (twelve months) positive effects sexual limitation (effect size 0.5) cancer worry (effect size 0.51) . exercise programs rt combined adt result consistent benefits cardiovascular fitness (standardised mean difference [smd], 0.83; 95% ci: 0.31–1.36; p < 0.01) muscle function (smd, 1.30; 95% ci: 0.53–2.07; p < 0.01) reduction urinary toxicity (smd, -0.71; 95% ci: -1.25 -0.18; p < 0.01) . men undergoing as, twelve weeks high-intensity interval training may improve cardiovascular fitness suppress psa progression . men post-surgical urinary incontinence, conservative management options include pelvic floor muscle training without biofeedback, electrical stimulation, extra-corporeal magnetic innervation (exmi), compression devices (penile clamps), lifestyle changes, combination methods. uncertainty around effectiveness value conservative interventions remains . surgical interventions including sling artificial urinary sphincter (aus) significantly decrease number pads used per day increase qol compared intervention. overall cure rate around 60% results improvement incontinence 25% . alternatives, adjustable transobturator male system (atoms) adjustable continence therapy (proact) may option seems less efficacious aus . detailed overview management urinary incontinence men see chapter 5.6 eau guidelines management non-neurogenic male luts . use pde5 inhibitors penile rehabilitation subject debate. single-centre, double-blind rct 100 men undergoing nerve-sparing surgery reported benefit nightly sildenafil (50 mg) compared on-demand use . however, multi-centre double-blind rct (n = 423) men aged < 68 years, normal pre-treatment erectile function undergoing either open, conventional robot-assisted laparoscopic nerve-sparing rp, tadalafil (5 mg) per day improved participants epic sexual domain-scores (least squares mean difference +9.6, 95% ci: 3.1–16.0) compared 20 mg ‘on demand’ placebo nine months follow-up, even though difference vanished end study . therefore, based discordant results, clear recommendation possible, even trend exists early use pde5 inhibitors rp penile rehabilitation . detailed discussion found eau sexual reproductive health guidelines . sr genitourinary cancers mostly prostate cancers evident sexual well-being concerns men partners evident diagnosis survivorship. (patient partners) benefited interventions many articulated difficulties initiating topic due embarrassment limited access interventions cancer services . testosterone regarding supplementation testosterone seems hesitation hcp. although evidence limited, men managed expectantly pca, received radical local therapy, worse outcomes receiving testosterone supplementation . therefore advise hesitate give testosterone substitution symptomatic hypogonadal men prostate cancer adt treatment choice. 8.3.2.2. men undergoing systemic treatments similar men treated radical approach (see above), men t1-t3 disease undergoing rt adt, combined nurse-led psychological support physiotherapist-led multi-disciplinary rehabilitation reported improvements qol. specifically, intervention involved action planning around patients’ needs related lifestyle changes, weight control, toilet habits, sexuality, psychological problems. complemented pelvic floor muscle therapy. improvements urinary (adjusted mean 4.5, 95% ci: 0.6–8.4), irritative (adjusted mean 5.8, 95% ci: 1.4–10.3) hormonal (adjusted mean 4.8, 95% ci: 0.8–8.8) epic domains found 22 weeks follow-up . three-year follow-up 92% response rate initial study, fewer participants moderate-severe bowel problems intervention (n = 2; 3%) vs. control group (n = 10; 14%) (p = 0.016) benefits terms urinary function maintained participants moderate-severe urinary problems baseline . providing supervised aerobic resistance exercise training moderate intensity improves eortc qlq-c30 role (adjusted mean 15.8, 95% ci: 6.6–24.9) cognitive domain outcomes (adjusted mean 11.4, 95% ci: 3.3–19.6) well symptom scales fatigue (adjusted mean 11.0, 95% ci: 20.2–1.7), nausea (adjusted mean 4.0, 95% ci: 7.4–0.25), dyspnoea (adjusted mean 12.4, 95% ci: 22.5–2.3) three months men treated adt . interventions also reported clinically relevant improvements fact-p (mean difference 8.9, 95% ci: 3.7–14.2) men long-term adt . findings supported sr reported improvements twelve weeks cancer-specific qol meta-analysis high-quality trials (smd 0.33, 95%, ci: 0.08–0.58) . supervised exercise interventions delivered twelve months effective reducing psychological distress; particularly men highest levels baseline anxiety depression . untrained older men, sr suggests lower volume exercise programs moderate-to-high intensity effective higher volume resistance training enhancing body composition, functional capacity muscle strength may reduce barriers exercise enhance adherence . another sr meta-analysis randomised trials shows exercise interventions patients adt result higher lean body mass (mean difference: 0.88, 95% ci 0.4 1.36, p < 0.01), lower body fat mass (mean difference: -0.93, 95% ci: -1.10 -0.10, p < 0.05), lower body fat rate (mean difference:-0.93, 95% ci: -1.39 -0.47, p < 0.01). greater efficacy noted exercise duration ≥ six months (vs. < six months) exercise immediately starting adt (vs. delayed exercise) . sr meta-analysis patients prostate cancer undergoing adt, supervised exercise therapy vs. therapy shows supervised exercise therapy probably superior exercise therapy improving ‘disease-specific quality life’ 0.43 (95%ci: 0.29, 0.58) ‘walking performance’ −0.41 (95% ci: −0.60, −0.22) moderate certainty evidence . sr meta-analysis determining factors affect adherence exercise programs, found exercise effects (p < 0.05) quality life fatigue. aerobic fitness, upper- lower-body strength significant effects (all p < 0.05) observed. adherence exercise-based interventions 80.38%, improvements observed aerobic fitness strength. subgroup analysis revealed exercise adherence impacted fatigue strength, greater improvements observed programs > twelve weeks . dietary intake adequate, vitamin calcium supplementation offered, evidence vitamin calcium modest effects bone men adt . online tools available calculate daily calcium intake individual patients. vitamin deficiency dose least 800 iu/day colecalciferol recommended. use 25(oh) assay may helpful measure vitamin levels . anti-resorptive therapy recommended men adt > six months either bmd t-score < -2.5 additional risk factor osteoporosis annual bone loss confirmed exceed 5%, cases severe fracture. referral bone specialist considered complex cases severe fracture and/or multiple risk factors. alendronate, risedronate, zoledronate denosumab shown prevent bone loss men hormone-sensitive locally-advanced metastatic pca adt [1474-1477]. patients warned < 5% risk osteonecrosis jaw and/or atypical femoral fractures associated drugs. bisphosphonates increase bmd hip spine 7% one year . optimal regimen zoledronic acid men adt hormone-sensitive locally-advanced metastatic pca remains unclear: quarterly yearly injections. question relevant risk jaw necrosis dose- time-related . quarterly regimen considered bmd ≤ 2.5 yearly injection unlikely provide sufficient protection . care taken discontinuing treatment rebound increased bone resorption occur. m0 patients, denosumab shown increase lumbar bmd 5.6% compared 1% decrease placebo arm two years, using 60 mg subcutaneous regimen every six months . associated significant decrease vertebral fracture risk (1.5% vs. 3.9%, p = 0.006). benefits similar whatever age (< > 70 years), duration type adt, initial bmd, patient’s weight, initial bmi. benefit associated significant toxicity, e.g., jaw osteonecrosis delayed healing vertebral fractures. m0 patients, use higher dosage (120 mg every four weeks), delay bone metastases 4.2 months shown without impact os, increase side effects. therefore, later regimen cannot recommended. spartan phase iii study (apalutamide nmcrpc) , patients receiving apalutamide experienced falls frequently vs. receiving placebo (15.6% vs. 9.0%). final multivariable model, baseline patient characteristics older age, poor ecog, history neuropathy, α-blocker use study treatment, remained significantly associated fall. after-baseline clinical characteristics significantly associated time fall development neuropathy, arthralgia, weight loss fall. preventive interventions considered identified baseline conditions post-treatment neuropathy, arthralgia, weight decrease present, reduce risk fall. 8.3.2.3. decision regret several treatments curative intent localised pca available comparable ten-year os . vary terms incidence major side effects, including urinary symptoms, bowel symptoms compromised sexual functioning . reason, patients’ treatment preferences, weigh expected benefits likely side effects, central consideration shared decision-making making informed treatment decisions [1485-1487]. remains challenging, however, evaluate whether decision-making process viewed successful; is, whether choice treatment best reflects patient’s preferences expectations . according decision justification theory (djt), specific information treatment experiences lead regret decision regret needs better understood minimise future patients . 25% men pca undergoing either single combined modality treatments report experiencing worse side effects expected . urinary incontinence strongly correlates regret prostatectomy . unmet expectations comparable among treatment groups, except fatigue. fatigue less frequently reported worse expected patients received bt compared patients received rp ebrt. could explained less invasive treatment course bt comparison ebrt without adt rp . unmet expectations frequently reported patients positive surgical margins following surgery; passive role decision-making process; higher scores decisional conflict scale (i.e., uncertainty treatment decision). interestingly, positive surgical margins directly associated increased risk pc-related mortality . active participation support process forming preference increases chance choosing treatment line patients’ expectations [1487,1494-1496]. may seem desirable tailor patients’ role decision-making initial preference, particularly preference deferring advice clinician, result less decisional conflict regret. increasing patients’ knowledge regardless initial preference may actually preferable . 8.3.2.4. decision aids prostate cancer shared decision-making increase patients’ comfort confronted management decisions shown improve health outcome training seems needed health care professionals guiding patients . patient education decreased psa testing increased adherence protocols . autonomous active decision-making patients associated less regret prostatectomy regardless method chosen decision aids reduce decisional conflict . still, guidance needed optimise patients’ understanding options . patients prioritised effectiveness pain control mode administration risk fatigue confronted treatment choice metastasised pca . implementing decision aids clinical validity utility carefully evaluated distinguished . decision aid educate well promote shared decision-making optimise efficacy pay attention communicative aspects . 8.3.2.5. guidelines quality life men undergoing systemic treatments recommendationsstrength ratingoffer men androgen deprivation therapy (adt), twelve weeks supervised (by trained exercise specialists) combined aerobic resistance exercise.strongadvise men adt maintain healthy weight diet, stop smoking, reduce alcohol ≤ two units daily yearly screening diabetes hypercholesterolemia. ensure calcium vitamin meet recommended levels.strongoffer men radical treatment specialist nurse-led, multi-disciplinary rehabilitation based patients’ personal goals addressing incontinence, sexuality, depression fear recurrence, social support positive lifestyle changes.strongoffer men starting long-term adt dual emission x-ray absorptiometry (dexa) scanning assess bone mineral density.strongoffer anti-resorptive therapy men long term adt either bmd t-score < -2.5 additional clinical risk factor fracture annual bone loss adt confirmed exceed 5%.strong